Toon 1 - 5 resultaten van 5 Voor zoekopdracht 'Seyed Reza Mousavi (13223324)', zoektijd: 0,01s Verfijn jouw resultaten
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. door Seyed Reza Mousavi (13223324)

    Gepubliceerd in 2025
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. door Seyed Reza Mousavi (13223324)

    Gepubliceerd in 2025
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. door Seyed Reza Mousavi (13223324)

    Gepubliceerd in 2025
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. door Seyed Reza Mousavi (13223324)

    Gepubliceerd in 2025
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. door Seyed Reza Mousavi (13223324)

    Gepubliceerd in 2025
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: